Stockreport

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognizedCRC leads BOT+BAL clinical development: [Read more]